Who are S6G5T-3's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Duac® Gel / Differin® Gel, QM1114-DP, Product 55394.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/s6g5t-3.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

S6G5T-3 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

S6G5T-3 (S6G5T-3) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: topical retinoid. Area: Dermatology.

phase 3 topical retinoid sebaceous glands Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

S6G5T-3 (S6G5T-3) — Sol-Gel Technologies, Ltd.. S6G5T-3 is a topical gel formulation of a proprietary molecule that targets the sebaceous glands to treat acne.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
S6G5T-3 TARGET	S6G5T-3	Sol-Gel Technologies, Ltd.	phase 3	topical retinoid	sebaceous glands
Duac® Gel / Differin® Gel	Duac® Gel / Differin® Gel	Stiefel, a GSK Company	marketed	Topical antibiotic/antimicrobial combination (Duac®); Topical retinoid (Differin®)	Bacterial ribosome (clindamycin); Retinoic acid receptor (adapalene); Reactive oxygen species generation (benzoyl peroxide)
QM1114-DP	QM1114-DP	Galderma R&D	phase 3	topical retinoid	retinoic acid receptor
Product 55394	Product 55394	Medicis Global Service Corporation	phase 3	topical retinoid

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (topical retinoid class)

Galderma R&D · 2 drugs in this class
Medicis Global Service Corporation · 1 drug in this class
Sol-Gel Technologies, Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). S6G5T-3 — Competitive Intelligence Brief. https://druglandscape.com/ci/s6g5t-3. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing